https://www.selleckchem.com/pr....oducts/l-alpha-phosp
BACKGROUND We compared survival outcomes among patients who received either NAC or AC and RC. METHODS We identified patients in the National Cancer Data Base (NCD diagnosed with clinical T2-T4, N0, M0 urothelial carcinoma who underwent RC. Patients who received NAC were propensity matched by age, race, ethnicity, sex, insurance type, academic/research program, comorbidity, and clinical stage to patients receiving AC within 90 days of RC. Median survival was calculated using Kaplan-Meier analysis. Adjusted hazard ra
Like
Comment
Share
